Anterior Pelvic Prolapse Reconstruction With TiLOOP® PRO A Polypropylene Mesh

Not Applicable

Completed

• Conditions: Uterine Prolapse; Cystocele
• Interventions: Device: TiLOOP® PRO Plus A

• Registration Number: NCT02690220
• Lead Sponsor: pfm medical gmbh

Brief Summary

The purpose of this study is to determine the influence of anterior pelvic prolapse reconstruction with a titanized polypropylene mesh on patients quality of life.

Detailed Description

This multicentre, non-randomized, observational clinical investigation will be performed to obtain usability and postmarket information on the TiLOOP® pelvic floor reconstruction meshes and in particular to obtain the improvement of patients' quality of life.

It is expected that the patient's quality of life is meliorated after implantation of a TiLOOP® PRO A mesh. To verify this, it will be shown that by means of a validated questionnaire the subjective quality of life after 12 months is significantly better than before implantation.

Study Timeline

• Study Start: 2016-02-01
• Study First Submitted: 2016-02-05
• Study First Submitted QC: 2016-02-18
• Study First Posted: 2016-02-24
• Primary Completion: 2017-07-31
• Study Completion: 2017-07-31
• Status Verified: 2019-01
• Last Update Submitted: 2019-10-21
• Last Update Posted: 2019-10-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 54

Inclusion Criteria

1. Existence of a cystocele. Women with a symptomatic genital descensus: at least stage II (ICS-classification according POP-Q system). This applies to primary as well as recurrent intervention.
2. Patient is mentally able to understand the nature, aims, or possible consequences of the clinical investigation.
3. Patient information has been handed out and written consent is at hand.
4. Patient has attained full age (18 years or older).

Exclusion Criteria

1. Unfinished family planning, pregnancy or breast-feeding mother.
2. Known intolerance to the mesh-implants under investigation.
3. Lack of written patients' informed consent.
4. Lack of patient compliance regarding data collection, treatment or follow-up investigations in the scope of the protocol.
5. Patients with acute (within the last 12 months) carcinoma in the pelvic area.
6. Patients with history of radiotherapy in the pelvic area.
7. Patients with implanted anterior pelvic floor mesh.
8. Patient is institutionalized by court or official order (MPG §20.3).
9. Participation in another interventional clinical investigation.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
surgical mesh implantation	TiLOOP® PRO Plus A	Standard method to implant the TiLOOP® PRO A surgical mesh transvaginally. Women with a symptomatic genital descensus: at least stage II (ICS-classification according Pelvic Organ Prolapse Quantification System (POP-Q system)). This applies to primary as well as recurrent intervention.

Primary Outcome Measures

Name	Time	Method
Patient's Quality of Life	12 months	By means of a validated questionnaire it will be shown whether the subjective quality of life after 12 months is significantly better than before implantation.

Secondary Outcome Measures

Name	Time	Method
Patient's Quality of Life	6 months	The evaluation of changes in quality of life assessed by the P-QoL 6 months after implantation of the TiLOOP® PRO A surgical mesh compared to before implantation.
Adverse Events (AE)	6 weeks, 6 and 12 months	Assessment and analysis of all \[serious\] adverse events (\[S\]AEs) during the first 12 months after implantation along with a contextual placement of safety data based on current literature.
Feasibility Check of Mesh implantation	1 day	To evaluate mesh implantation, information about the duration of the procedure (minutes from cut to stitches) and the operability of the application set (easy, suitable, difficult, no set used) will be collected during the surgery. Taking together, this information will encapsulate the feasibility of the mesh implantation descriptively.
Number of complications and concomitant procedures	1 day	Counting the number of intraoperative complications (e. g. lesion of the bladder, the urethra or the intestines) and concomitant procedures (e. g. hysterectomy, colporrhaphy, vaginal sacrospinal fixation) procedure-related adverse events as assessed by CTCAE v4.0 and common concomitant procedures will be evaluated.

Trial Locations

Locations (5)

Klinikum Dresden-Friedrichstadt; 🇩🇪 Dresden, Sachsen, Germany

Klinikum Augsburg; 🇩🇪 Augsburg, Bayern, Germany

Ev. Amalie-Sieveking-Krankenhaus; 🇩🇪 Hamburg, Germany

Klinikum Oberlausitzer Bergland gemeinnützige GmbH; 🇩🇪 Zittau, Sachsen, Germany

Klinik Tettnang GmbH; 🇩🇪 Tettnang, Baden-Württemberg, Germany